Our Focus
Kinled has a longstanding track record of identifying, financing and supporting pioneering businesses developing breakthrough technologies across life sciences, advanced medical devices, robotics, precision medicine, drug discovery, neuromodulation and digital innovation.
The Aisher family has been founding, building and investing in innovative businesses for more than a century, establishing a legacy of entrepreneurship, industrial development and long-term capital investment.
Learn more about our origins and investment heritage through our family history.
Today, Kinled maintains a diversified portfolio of approximately 175 investments, held both directly and through specialised venture capital funds, with a particular focus on businesses developing transformative technologies with significant long-term commercial potential.
Life Sciences & Medical Technologies:
Representing over 50% of our portfolio, our life sciences investments focus on breakthrough innovations in biotechnology, precision medicine, drug discovery, advanced medical devices, surgical robotics, neuromodulation and next-generation healthcare technologies.
We seek to support companies developing differentiated, scientifically validated technologies capable of addressing significant unmet medical needs, improving clinical outcomes and transforming the delivery of healthcare, with a strong focus on neurology, cardiology, and oncology.
Deep Technology & Digital Innovation:
Representing approximately 25% of our portfolio, our digital technology investments increasingly focus on deep technology and the fundamental innovations shaping the next generation of computing, industrial systems and digital infrastructure.
Our investment interests encompass quantum computing, photonics, advanced semiconductors, artificial intelligence, robotics, next-generation computing architectures, industrial automation and enabling software technologies.
We favour businesses developing proprietary, defensible technologies with the potential to establish new industry standards, overcome fundamental technological limitations and create entirely new markets.
Our investment philosophy emphasises the convergence of advanced scientific research, engineering excellence and commercial application, particularly where breakthrough technologies can deliver substantial improvements in computing performance, energy efficiency, connectivity, industrial productivity and technological capability.
Alongside these frontier technologies, we continue to support selected software platforms, SaaS-enabled networks and digitally enabled business models that demonstrate strong scalability, sustainable competitive advantages and the potential to transform established industries.
Financial Technologies:
Representing approximately 25% of our portfolio, our fintech investments focus on companies using technology to modernise financial services, challenge established institutions and deliver more efficient, accessible and customer-centric solutions.
Our interests span embedded payments, digital banking, insurance technology, lending, real estate technology and financial infrastructure.
We favour scalable business models that leverage technology, automation and data intelligence to improve transparency, reduce transaction costs and create more efficient financial ecosystems.
Our Investment Partnerships:
In addition to our direct investments, Kinled participates as a Founding Partner, Director and/or Limited Partner in twelve independent investment funds, providing access to specialised expertise, proprietary deal flow and investment opportunities across multiple sectors and geographies.
These partnerships include:
-
Four dedicated life sciences investment vehicles managed from Vienna and Zurich, with combined assets under management of approximately €300 million.
-
Six digital technology and innovation funds, based in Vienna, Zurich, London/Copenhagen, Prague/Bratislava and Helsinki, have combined assets under management of approximately €225 million.
-
Two deep technology funds managed from Stuttgart and Innsbruck, focused on quantum computing, advanced semiconductors, artificial intelligence, industrial innovation, and next-generation computing infrastructure, with combined assets under management of €200 million.
Together, these relationships complement our direct investment activities and reinforce Kinled’s commitment to supporting exceptional entrepreneurs, breakthrough technologies and businesses with the potential to shape the industries of tomorrow.
Fostering Innovation
Kinled harbours a commitment to transforming academic and innovative ventures into thriving commercial entities.
In the last decade, Kinled has achieved this through privately funding three venture accelerators in Austria and Switzerland, and working with a suite of regulated funds designed to underpin these ventures.
Today we provide finance to research laboratories in Vienna, Austria, focused on neuro-degeneration, inflammation, oncology, and pulmonary disorders; and one accelerator in Santa Clara, USA, focused on cardiovascular solutions.
Moreover, our strategic co-investments with leading venture capital firms and family offices stand as a testament to our collaborative approach and our commitment to innovation.
Kinled has created a number of mechanisms to allow co-investment from sophisticated investors qualified family-offices, and entities that share our philanthropic ideals, who wish to support us in developing academic/scientific projects and nascent technologies.
Today all investments are managed via Hong Kong nominee agreements, Swiss simple partnership agreements, or through EU/US regulated funds.
Danube BioVentures - Danube BioVentures operates a series of venture capital funds geared towards pharmaceutical drug development and biomedical innovations emerging from early-stage projects. Working with over a dozen European Universities, and the United Nations Centre for Genetic Engineering and Biotechnology, Danube BioVentures provides investors with access to the evolving biotech and pharmaceutical sector, benefiting from the deep scientific and market knowledge of our strategic partners.
Opportunities
Kinled harbours a commitment to transforming academic ventures into thriving commercial entities.
This vision has been actualised through the establishment of three venture accelerators in Austria and Switzerland, along with a suite of regulated funds designed to underpin these ventures. Moreover, our strategic co-investments with leading venture capital firms and family offices stand as a testament to our collaborative approach and our commitment to innovation.
Kinled has created a number of mechanisms to allow co-investment from sophisticated and qualified family-offices who wish to support us in developing academic/scientific projects and nascent technologies.
Today all our investments are processed through independently-managed incubator/accelerators that Kinled is a founder shareholder in, and two EU regulated funds that we manage, as well as a special opportunity investment company that co-invests with a number of Swiss, EU, US, and UK regulated and un-regulated technology funds, that we are partners in.
Cebina The Central European Biotech Incubator & Accelerator at the University of Vienna’s Campus Biotech, supports innovative biotechnology companies focused on inflammation, neurology and ageing.
Mountain Labs is a start-up incubator and technology investment facilitator, sourcing new deep technology investment opportunities in artificial intelligence, quantum computing, and brain computer interface.
Danube BioVentures - Danube BioVentures operates a series of venture capital funds geared towards pharmaceutical drug development and biomedical innovations emerging from early-stage projects, with a strong focus on dementia. Working with over a dozen European Universities, and the United Nations Centre for Genetic Engineering and Biotechnology, Danube BioVentures provides investors with access to the evolving biotech and pharmaceutical sector, benefiting from the deep scientific and market knowledge of our strategic partners.
Our Due Diligence Process
A significant part of our strategy is based upon our superior deal flow and extremely rigorous due diligence.
Our executives are principally managed from offices from Hong Kong, Switzerland and Austria. We also have offices in Gibraltar, London & Shanghai. In the US, Kinled has 16 portfolio businesses, and we work closely with a number of specialised investors across the country, frequently co-investing with technology experts and renowned University alumni.
We like to stay close to our founders, entrepreneurs, and are an active investor, meaning that our team, or fund partners, take an active role in the management and direction of our portfolio companies, using our shareholding position to positively influence business strategy.
There are areas that we have really specific expertise in, where we believe our industry expertise is unparalleled. We are dedicated to drug discovery and pioneering research into tangible solutions for severe illness, as well as to emerging fields of regenerative medicine, robotics, bionics, financial and digital technologies.
Annually we see over 2000 business plans, leading to 150 pre-screened opportunities to complete deep due diligence on - knowing that they have been approved by the most rigorous legal and commercial team in the industry, and generally invest in 2 to 4 companies.
Family Office
We are often asked whether Kinled is a “Family Office.” Our Chairman, Patrick Aisher, doesn’t hesitate:
“Absolutely not. ‘Family Office’ is a dreadful term—dreamt up by banks, accountants, and consultants to describe a rigid, generic structure that exists purely to preserve wealth, inflate egos, and rack up fees for advisors.” At Kinled, we believe in creating wealth—not just financial, but in opportunity, purpose, and progress—for our partners, team members, co-investors, and portfolio and fund shareholders. We’re proud to do so alongside carefully selected funds and investment vehicles, some of which we manage directly, and some managed by other trusted partners.
Sir Owen Aisher – (1900-1993)
Jack Aisher – (1910-2008)
Owen Aisher – (1876-1963)
Patrick Aisher
Funds
10% of our investments are through specialised funds.
Over the years, Kinled has seeded, created, invested, and partnered with a number of regulated and unregulated funds. Today we are proud to be a Founding/Limited Partner in the following 10 funds. Four are dedicated Life Science investment companies managed from Vienna and Zurich, with combined Assets under Management of €300M; and six are Digital Technology Funds based in Vienna, Zurich, London, Prague, Bratilslava, and Helsinki, with Assets under Management of €225M.
Please click here to learn more about our portfolio of 175 investments, access our private client site, or see our locations
Our Portfolio
